The Relation of Urinary Estrogen Metabolites with Mammographic Densities in Premenopausal Women

Overview

Journal Cancer Epidemiol

Publisher Elsevier

Specialties Oncology
Public Health

Date 2012 Apr 28

PMID 22537763

Citations 4

Authors

Gertraud Maskarinec

Sreang Heak

Yukiko Morimoto

Laurie Custer

Adrian A Franke

Affiliations

Soon will be listed here.

Abstract

Background: Mammographic density is a strong predictor of breast cancer risk. The total amount and the metabolism of endogenous estrogens, e.g., the ratio of 2-hydroxyestrone (2-OHE(1)) and 16α-OHE(1) may influence breast cancer risk. This study examined the association of urinary estrogen metabolites with breast density in premenopausal women.

Methods: Urine samples were collected at baseline and after 2 years, analyzed for 11 estrogen metabolites plus progesterone and testosterone by liquid chromatography mass spectrometry, and adjusted for creatinine levels. Mixed-effects regression was applied to examine the association of estrogens with breast density.

Results: Total estrogen metabolites (181 ± 113 vs. 247 ± 165 pmol/mg creatinine, p=0.01) and the 2/16α-OH ratio (8.4 ± 10.4 vs. 13.0 ± 17.1, p=0.02) were lower in the 74 Asian than in the 114 non-Asian women. In adjusted models, positive associations of total estrogen metabolites (p=0.002) and the 2/16α-OHE(1) ratio (p=0.08) with percent density were detected in Asians only. In all women, mammographic density was positively associated with the 2-OH pathway (p=0.01), inversely related to the 16α-OH pathway (p=0.01), and not associated with the 4-OH pathway, testosterone, and progesterone. Results for the size of the dense area weakly reflected the findings for percent density, while associations with the non-dense area were in the opposite direction.

Conclusions: The findings that the 2-OH pathway is associated with higher and the 16α-OH pathway with lower breast density contradicts the hypothesized risk profile of these metabolites, but, if a relation between estrogen metabolites and breast cancer risk exists, it may be mediated through pathways other than mammographic density.

Citing Articles

CYP3A7*1C allele is associated with reduced levels of 2-hydroxylation pathway oestrogen metabolites.

Sood D, Johnson N, Jain P, Siskos A, Bennett M, Gilham C Br J Cancer. 2017; 116(3):382-388.

PMID: 28072767 PMC: 5294487. DOI: 10.1038/bjc.2016.432.

Relationship of serum estrogens and metabolites with area and volume mammographic densities.

Gierach G, Patel D, Falk R, Pfeiffer R, Geller B, Vacek P Horm Cancer. 2015; 6(2-3):107-19.

PMID: 25757805 PMC: 4558904. DOI: 10.1007/s12672-015-0216-3.

Cyclic endogenous estrogen and progesterone vary by mammographic density phenotypes in premenopausal women.

Iversen A, Frydenberg H, Furberg A, Flote V, Finstad S, McTiernan A Eur J Cancer Prev. 2015; 25(1):9-18.

PMID: 25714648 PMC: 4885541. DOI: 10.1097/CEJ.0000000000000130.

Urinary estrogens and estrogen metabolites and mammographic density in premenopausal women.

Bertrand K, Eliassen A, Hankinson S, Gierach G, Xu X, Rosner B Breast Cancer Res Treat. 2012; 136(1):277-87.

PMID: 23053640 PMC: 3475411. DOI: 10.1007/s10549-012-2240-0.

References

Martin L, Minkin S, Boyd N . Hormone therapy, mammographic density, and breast cancer risk. Maturitas. 2009; 64(1):20-6. DOI: 10.1016/j.maturitas.2009.07.009. View

Pettersson A, Hankinson S, Willett W, Lagiou P, Trichopoulos D, Tamimi R . Nondense mammographic area and risk of breast cancer. Breast Cancer Res. 2011; 13(5):R100. PMC: 3262213. DOI: 10.1186/bcr3041. View

Shimizu H, Ross R, Bernstein L, Pike M, Henderson B . Serum oestrogen levels in postmenopausal women: comparison of American whites and Japanese in Japan. Br J Cancer. 1990; 62(3):451-3. PMC: 1971457. DOI: 10.1038/bjc.1990.316. View

Ursin G, Ma H, Wu A, Bernstein L, Salane M, Parisky Y . Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev. 2003; 12(4):332-8. View

Riza E, dos Santos Silva I, De Stavola B, Bradlow H, Sepkovic D, Linos D . Urinary estrogen metabolites and mammographic parenchymal patterns in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2001; 10(6):627-34. View

Xu X, Veenstra T, Fox S, Roman J, Issaq H, Falk R . Measuring fifteen endogenous estrogens simultaneously in human urine by high-performance liquid chromatography-mass spectrometry. Anal Chem. 2005; 77(20):6646-54. DOI: 10.1021/ac050697c. View

Pike M, Kolonel L, Henderson B, Wilkens L, Hankin J, Feigelson H . Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites. Cancer Epidemiol Biomarkers Prev. 2002; 11(9):795-800. View

Yong M, Schwartz S, Atkinson C, Makar K, Thomas S, Stanczyk F . Associations between polymorphisms in glucuronidation and sulfation enzymes and sex steroid concentrations in premenopausal women in the United States. J Steroid Biochem Mol Biol. 2011; 124(1-2):10-8. PMC: 3065887. DOI: 10.1016/j.jsbmb.2010.12.014. View

Falk R, Xu X, Keefer L, Veenstra T, Ziegler R . A liquid chromatography-mass spectrometry method for the simultaneous measurement of 15 urinary estrogens and estrogen metabolites: assay reproducibility and interindividual variability. Cancer Epidemiol Biomarkers Prev. 2008; 17(12):3411-8. PMC: 4158914. DOI: 10.1158/1055-9965.EPI-08-0355. View

10.

Yager J, Liehr J . Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol. 1996; 36:203-32. DOI: 10.1146/annurev.pa.36.040196.001223. View

11.

Setiawan V, Haiman C, Stanczyk F, Le Marchand L, Henderson B . Racial/ethnic differences in postmenopausal endogenous hormones: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev. 2006; 15(10):1849-55. DOI: 10.1158/1055-9965.EPI-06-0307. View

12.

Byng J, Boyd N, Fishell E, Jong R, Yaffe M . The quantitative analysis of mammographic densities. Phys Med Biol. 1994; 39(10):1629-38. DOI: 10.1088/0031-9155/39/10/008. View

13.

Im A, Vogel V, Ahrendt G, Lloyd S, Ragin C, Garte S . Urinary estrogen metabolites in women at high risk for breast cancer. Carcinogenesis. 2009; 30(9):1532-5. PMC: 2736301. DOI: 10.1093/carcin/bgp139. View

14.

Trichopoulos D, Yen S, Brown J, Cole P, MacMahon B . The effect of westernization on urine estrogens, frequency of ovulation, and breast cancer risk. A study of ethnic Chinese women in the Orient and the USA. Cancer. 1984; 53(1):187-92. DOI: 10.1002/1097-0142(19840101)53:1<187::aid-cncr2820530133>3.0.co;2-n. View

15.

Maskarinec G, Robbins C, Riola B, Kane-Sample L, Franke A, Murphy S . Three measures show high compliance in a soy intervention among premenopausal women. J Am Diet Assoc. 2003; 103(7):861-6. DOI: 10.1016/s0002-8223(03)00377-8. View

16.

Franke A, Lai J, Halm B, Pagano I, Kono N, Mack W . Equol production changes over time in postmenopausal women. J Nutr Biochem. 2011; 23(6):573-9. PMC: 3901250. DOI: 10.1016/j.jnutbio.2011.03.002. View

17.

Yong M, Schwartz S, Atkinson C, Makar K, Thomas S, Newton K . Associations between polymorphisms in glucuronidation and sulfation enzymes and mammographic breast density in premenopausal women in the United States. Cancer Epidemiol Biomarkers Prev. 2010; 19(2):537-46. PMC: 2820123. DOI: 10.1158/1055-9965.EPI-09-0898. View

18.

Eliassen A, Spiegelman D, Xu X, Keefer L, Veenstra T, Barbieri R . Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women. Cancer Res. 2011; 72(3):696-706. PMC: 3271178. DOI: 10.1158/0008-5472.CAN-11-2507. View

19.

Setchell K, Brown N, Lydeking-Olsen E . The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr. 2002; 132(12):3577-84. DOI: 10.1093/jn/132.12.3577. View

20.

Franke A, Custer L, Morimoto Y, Nordt F, Maskarinec G . Analysis of urinary estrogens, their oxidized metabolites, and other endogenous steroids by benchtop orbitrap LCMS versus traditional quadrupole GCMS. Anal Bioanal Chem. 2011; 401(4):1319-30. PMC: 3249142. DOI: 10.1007/s00216-011-5164-3. View